Kite Pharma Meets Primary Endpoint In Study Of Non-Hodgkin Lymphoma Drug

Kite Pharma said it met the primary endpoint of objective response rate in its ZUMA-1 trial of a drug for patients with Non-Hodgkin Lymphoma.

The study examined Kite’s axicabtagene ciloleucel in a population of 111 patients with diffuse large B-cell lymphoma, primary mediastinal B-cell lymphoma, or transformed follicular lymphoma.

A total of 79% of patients achieved an objective response rate and 52% achieved a complete response rate, the company said.

Kite plans to seek regulatory approval of axicabtagene ciloleucel in refractory aggressive NHL and complete its rolling submission of the biologics license application in Q1 2017.

Leave a Comment